SEC Form 4 · accession 0001840199-26-000091
Waldencast plc · WALD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Manuel Manfredi
Officer — Chief Financial Officer
Period of report
Jul 30, 2026
Accepted (ET)
Aug 7, 2026 · 4:10 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001840199
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Class A Ordinary Shares | Jul 30, 2026 | M | 79,289 | $0.00 | A | 118,933 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF2,F3 | — | Jul 30, 2026 | M | 79,289 | D | — | — | Class A Ordinary Shares | 79,289 | 0 | D |
Explanation of responses
- F1Represents accelerated vesting of 79,289 outstanding restricted stock units ("RSUs") held by the reporting person in connection with the completion of the Issuer's sale of its Obagi Medical dermatological skincare and aesthetics business on July 30, 2026. Effective on the date of completion of such sale, the reporting person transitioned from the Issuer to lead Obagi Medical.
- F2Each RSU represents a contingent right to receive one Class A ordinary share, or an equivalent value in cash at the plan administrator's election.
- F3On October 30, 2024, the reporting person was granted 118,933 RSUs, which would have vested over a three-year period as follows: (i) 39,644 on October 1, 2025; (ii) 39,644 on October 1, 2026; and (iii) 39,645 on October 1, 2027.